Halozyme Therapeutics, Inc. (HALO)
68.52
-1.12
(-1.61%)
USD |
NASDAQ |
Jun 17, 16:00
68.52
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Enterprise Value : 10.08B for June 16, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 16, 2026 | 10.08B |
| June 15, 2026 | 10.27B |
| June 12, 2026 | 10.06B |
| June 11, 2026 | 10.21B |
| June 10, 2026 | 10.18B |
| June 09, 2026 | 10.30B |
| June 08, 2026 | 10.21B |
| June 05, 2026 | 10.30B |
| June 04, 2026 | 10.31B |
| June 03, 2026 | 10.10B |
| June 02, 2026 | 9.682B |
| June 01, 2026 | 9.902B |
| May 29, 2026 | 9.713B |
| May 28, 2026 | 9.907B |
| May 27, 2026 | 9.963B |
| May 26, 2026 | 9.971B |
| May 22, 2026 | 9.924B |
| May 21, 2026 | 9.947B |
| May 20, 2026 | 10.00B |
| May 19, 2026 | 9.972B |
| May 18, 2026 | 9.819B |
| May 15, 2026 | 9.781B |
| May 14, 2026 | 10.03B |
| May 13, 2026 | 10.13B |
| May 12, 2026 | 10.23B |
| Date | Value |
|---|---|
| May 11, 2026 | 9.697B |
| May 08, 2026 | 9.426B |
| May 07, 2026 | 9.553B |
| May 06, 2026 | 9.690B |
| May 05, 2026 | 9.633B |
| May 04, 2026 | 9.479B |
| May 01, 2026 | 9.407B |
| April 30, 2026 | 9.371B |
| April 29, 2026 | 9.300B |
| April 28, 2026 | 9.395B |
| April 27, 2026 | 9.470B |
| April 24, 2026 | 9.573B |
| April 23, 2026 | 9.718B |
| April 22, 2026 | 9.933B |
| April 21, 2026 | 9.934B |
| April 20, 2026 | 10.07B |
| April 17, 2026 | 10.04B |
| April 16, 2026 | 9.724B |
| April 15, 2026 | 9.892B |
| April 14, 2026 | 9.804B |
| April 13, 2026 | 9.765B |
| April 10, 2026 | 9.864B |
| April 09, 2026 | 9.777B |
| April 08, 2026 | 9.581B |
| April 07, 2026 | 9.364B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 109.91B |
| Agenus, Inc. | 377.50M |
| Altimmune, Inc. | 45.44M |
| Lineage Cell Therapeutics, Inc. | 246.99M |
| Amgen, Inc. | 233.01B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 150.05M |
| Revenue (Quarterly) | 376.71M |
| Total Expenses (Quarterly) | 226.66M |
| EPS Diluted (Quarterly) | 1.221 |
| Gross Profit Margin (Quarterly) | 71.13% |
| Profit Margin (Quarterly) | 39.83% |
| Earnings Yield | 4.06% |
| Operating Earnings Yield | 10.30% |
| Normalized Earnings Yield | 7.121 |